Patient screening to begin this month
DURHAM, NC, April 20, 2026 – Atsena Therapeutics, a clinic…
Discover the Latest
Articles
04/20/2026
Atsena Therapeutics Receives Data Monitoring Committee Recommendation to Proceed with Pivotal Part C Cohort of Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis
04/06/2026
Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital
- Agreement includes up to $155 million in non-dilutive funding with an upfront payment of $35 millio…
02/27/2026
Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting
Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-rel…
01/27/2026
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa
The trial is funded through Abu Dhabi’s Healthcare Research and Innovation Fund.
Clinical developmen…
01/20/2026
Genezen and Atsena Therapeutics Announce Strategic Commercial Manufacturing Partnership
Lexington, MA and Durham, NC – [January 20, 2026] – Genezen, a leading gene therapy contract develop…
01/08/2026
Beacon Therapeutics Announces Closing of Oversubscribed Series C Financing for Over $75 Million
- Round led by new investor Life Sciences at Goldman Sachs Alternatives with participation by new inv…
11/13/2025
Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease
Emerging gene therapy administered through a one-time subretinal injection marks a major milestone f…
10/28/2025
SparingVision Doses First Patient with SPVN20 for Advanced Retinitis Pigmentosa in NYRVANA Trial
- SPVN20 aims to restore visual acuity and aspects of color vision by creating an alternative light-s…
09/30/2025
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolera…
09/23/2025
Atsena Therapeutics Announces Dosing Complete for Adults in Part B of the Phase I/II/III LIGHTHOUSE Trial Evaluating ATSN-201 to Treat X-linked Retinoschisis
Pediatric dosing expected to begin in Q4 2025
Pivotal cohort expected to begin enrolling in Q1 2026…
09/12/2025
Nacuity Pharmaceuticals Announces Positive Data from Clinical Trial Evaluating NPI-001 to Treat Retinitis Pigmentosa Associated with Usher Syndrome
NPI-001 shows more than 50% reduction in photoreceptor loss caused by RP associated with USH over tw…
07/23/2025
Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness
- Collaboration aims to accelerate development of OPGx-RDH12, a gene therapy for RDH12-associated Leb…
07/09/2025
Atsena Therapeutics Releases XLRS Community Statement
This morning, Atsena issued a press release to announce that they have achieved alignment with the F…
06/23/2025
Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program
RESEARCH TRIANGLE PARK, N.C., June 23, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a…
06/09/2025
SparingVision appoints Dr. Kali Stasi as Chief Medical Officer
- Experienced global leader in ophthalmology and gene therapy to advance SparingVision’s clinical pro…
04/08/2025
Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases
First pediatric patient shows encouraging early safety profile and meaningful improvement in visual …
04/02/2025
Atsena Therapeutics Announces Oversubscribed $150 Million Series C Financing to Further Advance Ocular Gene Therapy Programs
Financing led by new investor Bain Capital with participation from new investor Wellington Managemen…
02/18/2025
Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program
First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the…
02/18/2025
Perceive Pharma Attracts $15M Series A Financing to Advance Ophthalmic Neuroprotection
Funding to fuel company's progress in driving lead glaucoma program to clinical readiness; industry …
01/21/2025
Nacuity Pharmaceuticals Granted U.S. FDA Fast Track Designation for NPI-001 (N-acetylcysteine amide) Tablets for the Treatment of Retinitis Pigmentosa
FORT WORTH, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical-stage…
11/13/2024
Nippon Shinyaku and Atsena Therapeutics Enter into an Exclusive Strategic Collaboration for ATSN-101 in the U.S. and Japan
Nippon Shinyaku and Atsena Therapeutics Enter into an Exclusive Strategic Collaboration for ATSN-101…
10/25/2024
The RD Fund Announces Ocuphire Pharma’s Acquisition of Opus Genetics
The resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD)
R…
10/24/2024
SparingVision Presents Updates on PRODYGY Trial and PHENOROD2 Study at ESGCT 2024
First oral presentation on PRODYGY at a major cell and gene therapy-focused conference
Completion of…
10/22/2024
Ocuphire Pharma Announces Acquisition of Opus Genetics
Acquisition creates a leading, clinical-stage company focused on the development of gene therapy tre…
09/23/2024
SparingVision Reports Progress on SPVN06 at Major Ophthalmology Conferences
SPVN06 demonstrates continued favorable safety profile at 12 months for low dose and 6 months for me…
09/05/2024
Atsena Therapeutics Announces 12-Month Safety and Efficacy Data from Phase I/II Clinical Trial of ATSN-101 in LCA1 Published in The Lancet
Atsena Therapeutics Announces 12-Month Safety and Efficacy Data from Phase I/II Clinical Trial of AT…
08/20/2024
Opus Genetics Receives Rare Pediatric Disease Designation from the U.S. FDA for Ocular Gene Therapy OPGx-LCA5 to Treat Rare Inherited Retinal Disease LCA5
Priority Review Voucher would be issued upon approval of OPGx-LCA5
RESEARCH TRIANGLE PARK, N.C., Aug…
08/14/2024
Atsena Therapeutics Receives Rare Pediatric Disease Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
Priority Review Voucher would be issued upon approval of ATSN-201
Second RPD and potential PRV for A…
06/18/2024
Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing Therapeutics Targeting Neurological Diseases
Ascidian to receive $42 million in initial payment, and up to $1.8 billion in research, clinical and…
06/13/2024
Opus Genetics Announces $1.7 Million in Project-based Funding from the Foundation Fighting Blindness to Support Two Preclinical Programs
$1M TRAP award to support preclinical safety study for gene therapy vector targeting rhodopsin- RHO-…
05/13/2024
SparingVision Presents One Year Results from the PHENOROD2 Natural History Study and Preliminary SPVN06 Safety Data at Key Congresses
• First analysis from PHENOROD2, one of the largest prospective natural history studies in RCD pati…
05/01/2024
Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase I/II Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)
- Subretinal injection of ATSN-201 was well tolerated in all patients in the first cohort with extens…
04/30/2024
Nacuity Pharmaceuticals Announces First Patients Implanted in Final Cohort of Phase 1/2 Clinical Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progression
Two patients have been implanted in the final cohort of the trial
Final cohort is actively enrolling …
04/17/2024
SalioGen Therapeutics Announces Selection Of Development Candidate For ABCA4-Mediated Stargardt Disease
SGT-1001 is the first development candidate using SalioGen’s novel Gene CodingTM technology for gene…
04/16/2024
Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Emmett Cunningham, Jr.
Ophthalmology industry veteran brings 20 years of experience as a life science investor and entrepre…
03/26/2024
Opus Genetics Announces Completion of Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy OPGx-LCA5 in Patients with Rare Inherited Retinal Disease LCA5
OPGx-LCA5 will advance to the next highest dose in mid-2024 based on positive safety and efficacy da…
02/15/2024
Nacuity Pharmaceuticals Announces Expansion of its Business Advisory Board with Appointment of Rare Disease Advocate Daniel Feller
FORT WORTH, Texas, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage…
02/08/2024
SparingVision Presents Initial SPVN06 Safety Data at the Macula Society 47th Annual Meeting
• No serious adverse events in the first two cohorts of patients dosed with SPVN06 (N=6)
• Observe…
12/08/2023
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and u…
12/04/2023
Atsena Therapeutics Announces Positive 12-month Safety and Efficacy Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)
ATSN-101 continues to demonstrate clinically meaningful improvements in vision at the highest dose a…
11/14/2023
Atsena Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ATSN-101 Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis (LCA1)
RMAT designation recognizes the potential of ATSN-101 to address unmet medical needs for patients wi…
11/03/2023
New Preliminary Clinical Data on Potential of Opus AAV-based Gene Therapy for Rare Inherited Retinal Disease to be Presented at the American Academy of Ophthalmology Annual Conference 2023
Data to be presented as part of gene augmentation therapy presentation
RALEIGH, N.C., Nov. 03, 2023 …
10/16/2023
The Retinal Degeneration Fund Announces an Investment in NVasc
NVasc is developing a therapeutic angiogenesis strategy for the treatment of retinal ischemia associ…
09/26/2023
SparingVision Selects Second Target in Strategic Collaboration with Intellia Therapeutics
Milestone broadens partnership to develop novel ocular therapies using CRISPR-based technologies.
Fir…
09/07/2023
Opus Genetics Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy OPGx-LCA5 in Patients with Rare Inherited Retinal Disease LCA5
OPGx-LCA5 is designed to address vision loss due to Leber congenital amaurosis associated with mutat…
08/30/2023
SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial
- Lead gene therapy asset, SPVN06, reported to be well-tolerated in first dosed cohort at low dose w…
08/24/2023
The Retinal Degeneration Fund announces an investment in Amber Bio
Amber Bio is developing a first-of-its-kind RNA writing platform using multi-kilobase edits to reach…
08/03/2023
Amber Bio Raises $26 Million Seed Financing Co-Led by Playground Global and Andreessen Horowitz to Advance New RNA-Based Gene Editing Platform
Amber Bio’s proprietary platform leverages multi-kilobase RNA editing and AI foundation models to ex…
08/01/2023
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
Agreement provides ProQR with initial payment of €12.5M and up to €135M in further payments, as well…
07/11/2023
Nacuity Pharmaceuticals Advances Phase 1/2 Clinical Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progression
New clinical site added and early safety signals observed in trial for treatment of ocular disease c…
06/09/2023
The Retinal Research Community Mourns the Loss of Retinal Research Pioneer Thierry Léveillard
Dr. Léveillard helped discover and develop a gene-agnostic, cone-preserving therapy for retinitis pi…
05/31/2023
Nacuity Pharmaceuticals Achieves Target Enrollment for Phase 1/2 Clinical Trial of NPI-001 for the Treatment of Retinitis Pigmentosa Associated with Usher Syndrome
Phase 1/2 SLO-RP trial completed target enrollment of 48 patients diagnosed with RP associated with …
05/22/2023
SparingVision Presents New Data on SPVN20 Program at ASGCT 2023
- First oral presentation on SPVN20 in a major scientific and medical conference
- SPVN20 is a gene the…
05/01/2023
Atsena Therapeutics Receives FDA Clearance of IND Application for ATSN-201, an Investigational Gene Therapy for the Treatment of X-linked Retinoschisis
ATSN-201 leverages AAV capsid that spreads laterally beyond subretinal injection site to facilitate …
04/27/2023
SparingVision Presents Progress of its Lead Gene Therapy Program SPVN06 at ARVO 2023
Paris, April 27, 2023 – SparingVision (“the Company”), a clinical-stage genomic medicine company dev…
04/25/2023
Atsena Therapeutics Announces Positive 6-month Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)
ATSN-101 demonstrated clinically meaningful improvements in vision at the highest dose with no drug-…
02/28/2023
RD Fund Appoints Mark S. Blumenkranz, MD, MMS to Board of Directors
Ophthalmology visionary Mark S. Blumenkranz, MD, MMS, to join RD Fund’s Board.
RALEIGH, North Caroli…
01/06/2023
The Retinal Degeneration Fund invests in a $78M Series B for Perceive Biotherapeutics
The investment supports the clinical development of two novel programs, both with the aim of being p…
12/28/2022
Opus Genetics Announces Acquisition of the Rights to Two Gene Therapy Product Candidates for Inherited Retinal Diseases
Opus to advance preclinical development programs for BEST1- and RHO-related retinal diseases
Deal ex…
12/01/2022
SparingVision's lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa
SparingVision set to advance into the clinic with breakthrough gene-independent approach targeting r…
12/01/2022
Opus Genetics Receives FDA Clearance of IND Application for OPGx-001, a Gene Therapy Candidate Intended for the Treatment of Rare Inherited Retinal Disease LCA5
OPGx-001 is Opus’ first program to enter clinical evaluation and is designed to address vision loss …
11/10/2022
Foundation Launching its Largest Natural History Study to Date for 1,500 People with Inherited Retinal Diseases Caused by Rare Mutated Genes
Uni-Rare Study will improve clinical understanding of more IRDs and boost development of potential t…
11/08/2022
Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Russell Kelley
Managing director of the Retinal Degeneration Fund joins board of directors
FORT WORTH, TX – Nov. 8,…
11/08/2022
Atsena Therapeutics Expands Leadership Team with Appointment of Lis Leiderman, MD, MBA, as Chief Financial Officer and Chief Business Officer
Biotech leader brings extensive experience in finance, business development and corporate strategy
D…
10/12/2022
Ascidian Therapeutics Launches to Rewrite RNA
ATP incubated and built Ascidian with $50 million in Series A funding
Pioneering RNA exon editing pl…
10/03/2022
Atsena Therapeutics Announces Positive Results from Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1)
ATSN-101 demonstrated clinically meaningful improvements in vision with no drug-related serious adve…
09/27/2022
Opus Genetics Expands Board of Directors with Appointment of Global Ophthalmology Leader Dr. Adrienne Graves
RESEARCH TRIANGLE PARK, N.C., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first gene…
09/15/2022
RD Fund Participates in a €75 Million Series B for SparingVision
Proceeds to fund first, in-human trials of breakthrough gene-agnostic therapy products and advance C…
08/12/2022
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs
- In line with corporate strategy update in April, ProQR to focus exclusively on the development of t…
07/27/2022
Atsena Therapeutics Announces Opening of New Office and Laboratory Space in North Carolina’s Research Triangle
World-class facility supports the company’s growth, and discovery and development of gene therapies …
07/21/2022
Opus Genetics Expands its Leadership Team
Vikram Arora, Ph.D., DABT, appointed Vice President of Non-Clinical Development
Erin O’Neil, M.D., a…
07/21/2022
RD Fund Announces New Chair, and Expansion of Board of Directors
RD Fund Board member and seasoned ophthalmology leader Adrienne Graves, PhD, appointed chair
Ophthal…
07/11/2022
Opus Genetics to Present at OIS Retina Innovation Summit 2022
Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal dise…
06/21/2022
Foundation Fighting Blindness Announces Leadership Changes
Jason Menzo named chief executive officer
Russell Kelley, PhD, MBA, appointed managing director of t…
06/15/2022
Nacuity Pharmaceuticals Announces $16.5 Million Series B Financing Led by Foundation Fighting Blindness & RD Fund
Funds to support advancement of two clinical trials through proof of concept: NPI-001 for ret…
05/11/2022
Opus Genetics Appoints Jennifer Hunt Chief Development Officer
Biopharma clinical development veteran to propel Opus’ AAV-based gene therapies for inherited retina…
03/08/2022
Foundation Fighting Blindness and InformedDNA Partner to Engage and Screen Patients for ProQR’s Pivotal Usher Syndrome and Retinitis Pigmentosa Clinical Trials
Trial recruitment is enabled by the Foundation Fighting Blindness’ patient registry, My Retina Track…
02/15/2022
Opus Genetics Appoints Brian Leising Vice President, Manufacturing
20-year biopharma industry veteran to lead manufacturing for Opus’ AAV-based gene therapies for inhe…
02/11/2022
ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10
ProQR has published the top-line results from the Phase 2/3 Illuminate Trial of sepofarsen in CEP290…
01/19/2022
Foundation Fighting Blindness Promotes Jason Menzo to President and Chief Operating Officer
Media Contact:
Chris Adams
Vice President, Marketing & Communications
cadams@fightingblindness.org
4…
01/06/2022
RD Fund Announces Series B Financing Behind SalioGen Therapeutics
Media Contact:
Chris Adams
410-423-0585
cadams@fightingblindness.org
Investment in new portfolio compan…
01/05/2022
SalioGen Therapeutics Closes $115 Million Oversubscribed Series B Financing to Advance Gene Coding™ – A New Category of Genetic Medicine
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) — SalioGen Therapeutics, a privately held biotechno…
12/16/2021
ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V…
12/09/2021
SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer
Paris, December 9, 2021 – SparingVision, a genomic medicine company developing vision-saving treatme…
12/06/2021
Gyroscope Therapeutics Announces Appointment of Tony Adamis to Board of Directors
LONDON—(BUSINESS WIRE)—Dec 6, 2021—Gyroscope Therapeutics Holdings plc, a clinical-stage gene therap…
12/02/2021
Startup spotlight: Opus Genetics, with $19M, works to advance cures for blinding retinal diseases
by Jason Parker, WRAL TechWire
RALEIGH – Opus Genetics recently announced it would open its third pr…
11/30/2021
Opus Genetics announces licensing of third program for inherited retinal disease
Opus Genetics announced an agreement to license its third preclinical program focused on an inherite…
11/11/2021
Opus Genetics Announces Agreement with Massachusetts Eye and Ear and Harvard Medical School to License Third Program for Inherited Retinal Disease
Program targets NMNAT1 gene based on the work of Opus scientific founder Dr. Eric Pierce
RALEIGH, N.…
11/08/2021
Opus Genetics Announces Presence at Eyecelerator@AAO 2021
Opus Genetics Announces Presence at Eyecelerator@AAO 2021
11/08/2021 | 08:34am EST
RALEIGH, N.C., No…
10/28/2021
RD Fund Announces Fundraising Efforts Underway for RD Fund 2
RD Fund Announces Fundraising Efforts Underway for RD Fund 2
Patient-centric venture philanthropy mo…
10/13/2021
Intellia beefs up ocular pipeline with 10% stake in SparingVision
Intellia beefs up ocular pipeline with 10% stake in SparingVision
by Kyle LaHucik |
Oct 13, 2021 7:…
10/13/2021
Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology
Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular The…
09/22/2021
RD Fund Launches Opus Genetics with $19M Seed Funding to Advance Gene Therapy Treatments for Blinding Conditions
RD Fund Launches Opus Genetics with $19M Seed Funding to Advance Gene Therapy Treatments for Blindin…
09/22/2021
Luxturna inventor Jean Bennett starts a new gene therapy company to tackle rare diseases left behind by pharma, VCs
Luxturna inventor Jean Bennett starts a new gene therapy company to tackle rare diseases left behind…
07/29/2021
To Get New Treatments Across the Finish Line, a Funder Fighting Blindness Turns to Investing
To Get New Treatments Across the Finish Line, a Funder Fighting Blindness Turns to Investing
July 2…
07/12/2021
Atsena Therapeutics Appoints Jennifer Wellman to Board of Directors
Atsena Therapeutics Appoints Jennifer Wellman to Board of Directors
July 12, 2021 07:30 ET | Source…
06/04/2021
Venture philanthropy: The secret weapon for unlocking biomedical research's full life-changing potential
Venture philanthropy: The secret weapon for unlocking biomedical research's full life-changing poten…
05/18/2021
Vedere Bio II Launches with $77 Million Series A Financing to Develop Next Generation Ocular Gene Therapies
Vedere Bio II Launches with $77 Million Series A Financing to Develop Next Generation Ocular Gene Th…
03/24/2021
ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials
- QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected …
03/19/2021
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
Paris, March 19, 2021 – SparingVision (“the Company”), a genomic medicine company developing vision …
02/04/2021
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision
Former Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and …
01/29/2021
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board
Paris, J…
12/16/2020
Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical Program, Two Preclinical Assets, and Novel Capsid Development for Ocular Diseases
Round was led by Sofinnova Investments with participation from Abingworth, Lightstone Ventures and a…
11/09/2020
Stargazer Pharmaceuticals, Inc. Announces $57 Million Series A Financing and Initiation of a Phase 2a Clinical Study of STG-001 in Stargardt Disease Patients
Stargazer Pharmaceuticals, Inc. Announces $57 Million Series A Financing and Initiation of a Phase 2…
10/29/2020
Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company
- Acquisition of Vedere Bio includes lead preclinical intravitreally-injected AAV gene therapy progra…
10/21/2020
SparingVision Raises €44.5 Million and Appoints Stéphane Boissel as Chief Executive Officer
Paris, October 21, 2020 – SparingVision (“the Company”), a genomic medicine company focused on ocula…
07/29/2020
Atsena Therapeutics acquires exclusive rights to Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis
DURHAM, N.C., July 29, 2020 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy c…
05/18/2020
Nacuity Pharmaceuticals Announces Initiation of SLO-RP (Safety and Efficacy of NPI-001 Tablets versus PLacebO for Treatment of Retinitis Pigmentosa Associated with Usher Syndrome) Phase 1/2 Clinical Trial
Nacuity Pharmaceuticals Announces Initiation of SLO-RP (Safety and Efficacy of NPI-001 Tablets versu…
04/28/2020
CheckedUp Launches Virtual Visits, Advanced Telehealth Platform for Specialty Care
CheckedUp Launches Virtual Visits, Advanced Telehealth Platform for Specialty Care
Advanced Telemedi…
03/31/2020
ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update
ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Ush…
07/09/2019
SparingVision Awarded at EIC Accelerator Program (H2020 SME Instrument Phase 2), Securing Funding of €2.5 Million
PARIS--(BUSINESS WIRE)--SparingVision, a biotechnology company specializing in the research and dev…
03/11/2019
ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
LEIDEN, Netherlands and CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.…
10/23/2018
Foundation Fighting Blindness Launches Retinal Degeneration Fund With More Than $70 million of Initial Funding
Today, the Foundation Fighting Blindness announced the creation of the first-ever Retinal Degenerati…
02/12/2018
Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A
- Foundation Fighting Blindness and ProQR enter into a partnership to develop QR-421a for Usher syn…
01/18/2018
Foundation Fighting Blindness Supporting Clinical Development of NACA, Promising New Drug for Many Forms of RP
The Foundation Fighting Blindness Clinical Research Institute (FFB-CRI) has announced an investment …
07/12/2017
SparingVision Formed to Advance Sight-Saving Protein for RP
The development of a vision-saving treatment for people with retinitis pigmentosa (RP) is getting a …
Load More